Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 29OTHER 4NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Endometrial Neoplasms 1

Interventions

Radiotherapy 302Cisplatin 266Cyclophosphamide 230Doxorubicin 177Paclitaxel 170Vincristine 162Carboplatin 152Filgrastim 140Etoposide 139Gemcitabine 118Docetaxel 114Fluorouracil 113Methotrexate 106Dexamethasone 106Cytarabine 106Prednisone 92Leucovorin 90Gene Expression Profiling 82Granulocyte Colony-Stimulating Factor 75Specimen Handling 70Magnetic Resonance Spectroscopy 63Irinotecan 59Capecitabine 59Radiation 54Polymerase Chain Reaction 51Ifosfamide 51Rituximab 49Immunohistochemistry 49Daunorubicin 49Oxaliplatin 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × ridaforolimus × Clear all
NCT00770185 2023-08-04

Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer

Canadian Cancer Trials Group

Phase 2 Completed
35 enrolled
Gynecologic

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡